Norris Medicines Limited has successfully completed a comprehensive regulatory audit conducted by Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC), marking a significant milestone in the company's international operations.

Audit Completion Details

The regulatory inspection was completed on December 9, 2025, following a thorough review of the company's operations. The audit results demonstrate Norris Medicines' commitment to maintaining high pharmaceutical standards across its manufacturing processes.

Scope of Inspection

The NAFDAC audit encompassed multiple critical areas of pharmaceutical operations, ensuring comprehensive compliance assessment:

• Quality systems evaluation
• Manufacturing practices review
• Documentation processes assessment
• Compliance parameters verification

The successful completion of this audit with no critical observations reflects the company's robust quality management systems and adherence to international pharmaceutical manufacturing standards.

Regulatory Compliance

Norris Medicines submitted this information to the stock exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company's proactive disclosure demonstrates its commitment to maintaining transparency with stakeholders regarding significant operational developments.

The successful NAFDAC audit completion strengthens Norris Medicines' position in the Nigerian pharmaceutical market and validates its manufacturing capabilities for international regulatory standards. This achievement supports the company's ongoing efforts to expand its presence in African markets while maintaining stringent quality controls.

Norris Medicines Limited has secured a significant legal victory with the Bombay High Court allowing its criminal appeal and setting aside a substantial deposit requirement. The pharmaceutical company informed the stock exchange about this favorable court ruling on December 11, 2025.

Court Ruling Details

The Bombay High Court's Criminal Appellate Jurisdiction delivered its order on November 19, 2025, allowing Criminal Appeal No. 89 of 2020 filed by Norris Medicines Limited. The appeal challenged a previous order passed under Section 8 of the Maharashtra Protection of Interest of Depositors (MPID) Act.

Legal Background and Implications

The original order under Section 8 of the MPID Act had directed the company and its director to deposit ₹1,32,92,359 along with simple interest at 18% per annum. However, the High Court's recent ruling has rendered this requirement infructuous.

The court's key observation centered on the outcome of MPID Special Case No. 3 of 2003, which resulted in acquittal. Based on this acquittal, the High Court determined that the order passed under Section 8 of the MPID Act could not be sustained, leading to the appeal being allowed and the deposit requirement being set aside.

Regulatory Compliance

Norris Medicines Limited has disclosed this development in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has indicated that a copy of the court order may be provided to the exchange upon request.

This legal victory eliminates a significant financial obligation for the company and resolves a long-standing legal matter that had been pending since 2020.